Celltrion Healthcare Australia Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
58 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for STEQEYMA ustekinumab 45 mg/0.5 mL solution for injection pre-filled syringe with safety guard.
-
Prescription medicine registrationActive ingredients: Omalizumab.
-
Prescription medicine decision summarySteqeyma (ustekinumab) has been approved to treat moderate to severe plaque psoriasis, active psoriatic arthritis, crohn's disease, and ulcerative colitis
-
Prescription medicine registrationActive ingredients: Ustekinumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VEGZELMA bevacizumab 400 mg/ 16 mL solution for intravenous infusion, vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VEGZELMA bevacizumab 100 mg/ 4 mL solution for intravenous infusion, vial.
-
Australian Public Assessment Report (AusPAR)Vegzelma (bevacizumab), in combination with fluoropyrimidine-based chemotherapy, has been approved for the treatment of metastatic colorectal cancer.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YUFLYMA adalimumab 80 mg/0.8 mL solution for injection pre-filled syringe in auto injector pen.
-
YUFLYMA adalimumab 80 mg/0.8 mL solution for injection pre-filled syringe with safety guard (396991)
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YUFLYMA adalimumab 80 mg/0.8 mL solution for injection pre-filled syringe with safety guard. -
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YUFLYMA adalimumab 80 mg/0.8 mL solution for injection pre-filled syringe.